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Role of CT colonography in 
screening programs
still under investigation [4]. Finally, follow-up 
studies since 1970 have supported the asso-
ciation between cigarette smoking and CRC; 
recent meta-ana lysis studies have confirmed a 
positive associa tion between smoking and colo-
rectal adenomas and CRC [6]. An even stronger 
correlation exists between smoking and non-
malignant colorectal polyps – in particular the 
hyperplastic-serrated types [7,8].
To explain the apparent paradox of smoking 
increasing the risk of cancer to a lesser extent 
than that of adenomas, it has been hypothesized 
that smoking may favor the development of can-
cer through the alternative hyperplastic-serrated 
pathway, which may give rise to approximately 
15% of CRC [9]. However, more epidemiological 
studies are needed to clarify such aspects.
Secondary prevention is the most effective 
way to reduce CRC mortality, through screen-
ing programs aimed at reducing the incidence 
of advanced disease. Approximately 80–90% 
of CRCs arise in pre-existing adenomatous 
polyps, following the so-called adenoma-
adenocarcinoma sequence, which is con sidered 
to a be a slow process spanning more than 
10 years [10]. 
Screening programs are likely to reduce mor-
tality in two ways. First, they allow identification 
of patients with small localized CRCs, whose 
treatment is associated with a high probability 
of long-term survival. Second, they interrupt 
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Colorectal cancer: epidemiology 
& rationale for screening
Colorectal cancer (CRC) heavily impacts on 
public health, being the third most common 
malignancy diagnosed among men and women 
in the Western world and having the second 
highest mortality. CRC accounts for approxi-
mately 210,000 deaths each year in Europe [1]. 
The 5-year survival rate is 90% if the disease is 
diagnosed while still localized in the submucosa, 
but only 68% for regional disease and 10% if 
distant metastases are present [2]. Recent trends 
in CRC mortality reveal a declining rate in the 
USA and in other industrialized countries since 
the mid-1980s, probably due to a combination 
of reduced exposure to risk factors, effect of 
screening on early detection and prevention, and 
improved treatment [3]. 
Colorectal cancer is a preventable disease. 
According to large observational and case–
control studies, fibers and antioxidants have 
been shown to be ineffective for primary pre-
vention [4]. Obesity is associated with CRC, 
but the role of fat and red-meat consumption 
is still uncertain [4]. Long-term prophylaxis 
with aspirin, nonsteroidal anti-inflammatory 
drugs and cox-2 inhibitors are effective for 
decreasing the risk of CRC, but side effects, 
such as gastrointestinal bleeding, limit their 
usefulness [5]. Prophylaxis with oral supple-
mentation of calcium, vitamin D and statins is 
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the progression to malignancy by removing pre-
malignant adenomatous lesions. Their removal 
is indeed associated with a reduction in the inci-
dence of CRC as demonstrated by the National 
Polyp Study in the USA and by other prospec-
tive and retrospective studies [11,12]. However, 
not all the adenomas have a potential for malig-
nancy; the accumulated evidence has demon-
strated that only the advanced adenomas (i.e., 
those that histologically are either ≥10 mm in 
size, have a villous component or a high grade 
of dys plasia) harbor a significant risk of malig-
nant transformation. They are thus considered, 
together with early CRCs, the target lesions for 
screening programs, under the definition of 
advanced neoplasia [13].
Colorectal cancer risk depends not only on 
the type of adenomas formed, but also on the 
individual’s family and personal history. A total 
of 75% of new cases of CRC occur in patients 
considered at an average risk: individuals aged 
50 years or older with no personal or family his-
tory of colorectal adenoma or CRC are represen-
tative of the general population and will benefit 
from any screening strategy.
The remaining 25% of new cases of CRC are 
associated with risk factors, which are impor-
tant to identify in order to stratify patients 
to appropriate initiation ages for screening 
and timing intervals for future examinations. 
Moderate-risk individuals are those with a fam-
ily or personal history of CRC or adenomas; 
they can easily be identified by a simple medical 
interview and be offered screening strategies at 
an earlier age than the general population [14]. 
A positive family history of CRC is generally 
defined as the presence of advanced neoplasia 
in any first-degree relative aged younger than 
60 years, or in at least two first-degree relatives 
at any age; in such cases, the relative risk is two- 
to four-fold compared with the general popula-
tion [14]. A positive personal history is consid-
ered in patients who underwent polyp ectomy 
of advanced adenomas or resection of CRC 
with curative intent. A two- to four-fold risk of 
CRC has been observed in patients whose index 
adenoma was advanced, and five- to six-fold 
in those with multiple adenomas [15]. Finally, 
high-risk individuals are those with heredi-
tary CRC syndromes, such as familial adeno-
matous polyp osis or hereditary non polyposis 
colon cancer; they are carriers of genetic muta-
tions with a risk to CRC ranging between 80 
and 100% [16,17]. Patients with long-standing 
chronic inflammatory bowel disease involving 
the colon are also included in the increased risk 
category [18]. The identification of high-risk 
individ uals is possible by a medical interview, 
and such individuals should be offered genetic 
counseling and diagnostic tests, including 
colonoscopy, according to specific guidelines. 
Although they represent approximately 10% of 
all CRC patients, emphasis should be given to 
identify high-risk individuals in order to initiate 
specific  surveillance programs.
In conclusion, CRC is a major public health 
problem whose burden not only affects the 
Western world but is also spreading to poor 
and underdeveloped countries. Mortality can 
be dramatically reduced by proper prevention 
programs, but increased awareness and motiva-
tion of health providers and the general public 
is essential to change its epidemiology.
Current status of screening programs 
in the general population 
& strategies for the prevention  
of colorectal cancer
Screening tests that reduce mortality from CRC 
fall into two categories (Table 1). The first cat-
egory comprises fecal tests, primarily aimed 
at the identification of early, asymptomatic, 
localized CRCs, whose treatment is associated 
with a high probability of long-term survival. 
The second category includes imaging tests 
aimed at identifying and then removing pre-
malignant lesions (adenomas), thus interrupting 
progression to their malignant transformation.
There is solid evidence from multiple random-
ized controlled trials that a screening program 
targeting individuals aged 50 years or older with 
repeated annual or biennial guaiac fecal occult 
blood tests (FOBTs) followed by colonoscopy in 
the positive subjects reduces CRC mortality; the 
most recent available update shows a 16% reduc-
tion (95% CI: 10–22%) after 12–18 years [19]. 
This figure is less than that observed after 
5–10 years, owing to an increase in incident 
cases in the screened population, likely derived 
from false-negative results, despite the presence 
of a  developing advanced adenoma.
In order to improve the outcome of the 
screening strategy and based on extrapolation 
of data from the literature, it has become clear 
that tests aimed at visualizating the colon may 
offer better accuracy than FOBTs do. Thus, 
flexible sigmoidoscopy, double-contrast barium 
enema and colonoscopy have been considered 
as alternative strategies with a longer follow-up 
interval than FOBTs, which could be efficiently 
implemented in average-risk individuals over 
50 years. This view has been officially endorsed 
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in the USA by the Preventive Services Task 
Force (USPSTF) [20]. Although several simula-
tion studies have demonstrated that population-
wide use of colonoscopy starting near the age of 
50 years may lead to approximately more than 
a 90% reduction in CRC mortality [21], this 
approach has not been implemented success fully 
and nor is there published evidence of mortal-
ity reduction using endoscopy-based screening 
programs, except for pending results from flex-
ible sigmoidoscopy screening studies in Italy, 
Norway, the UK and the Pittsburgh Cancer 
Institute (PA, USA) [22–25]. 
Endoscopic screening tests are indeed biased 
by several factors, such as potential harms, lim-
ited accessibility and scarce compliance by sub-
jects; furthermore, cost–effectiveness ana lysis 
has failed to demonstrate the superiority of any 
one of such tests over screening programs based 
on FOBTs [26]. As a result, both national guide-
lines and interventional screening programs rec-
ommend that the method for CRC screening 
should be individualized to patients, practice 
settings and availability of resources [27], con-
sidering that the main hindrance in effectively 
reducing mortality is not so much due to poor 
test accuracy but rather to their poor accep-
tance [28]. However, the somewhat low (16%) 
reduction in mortality demonstrated by popula-
tion screening with the guaiac FOBT is indeed 
partly due to its poor accuracy, thus an effort 
has been undertaken to develop fecal tests with 
better diagnostic accuracy. Available evidence 
has shown that fecal immunochemical occult 
blood testing and high-sensitivity guaiac FOBT 
offer better sensitivity and a more or less com-
parable specificity with the old guaiac test, and 
an advantage has been postulated in their use in 
screening programs [29]. Fecal DNA testing has 
been studied, but the sample size is too limited to 
recommend its use as a screening test, although 
it is already commercially available. There are 
concerns regarding the cost of the fecal DNA 
test, and the recommendations by the manufac-
turer to repeat screening at 5-year intervals is not 
 supported by enough evidence  [30,31].
Screening strategies identify patients at an 
increased risk in whom either one or more 
advanced adenomas or a localized CRC have 
been removed; they have a genetic pre disposition 
to form further adenomas potentially evolving 
into cancer [32,33]. Colonoscopy is generally indi-
cated for postpolypectomy and curative cancer 
resection follow-up, at variable intervals accord-
ing to the number and histological hallmarks 
of the removed lesions, age, family history and 
possibly tobacco smoking [31]. Nonetheless, 
even when considering patients with the most 
advanced lesions, adenoma recurrence is only 
approximately 20%, thus raising the question 
as to whether a less-invasive test may be per-
formed to avoid colonoscopy in patients who do 
not have recurrences. FOBT-based strategies are 
not appropriate for this purpose, whereas there is 
growing evidence that CT colonography (CTC) 
may be efficiently used instead.
Screening programs in the general population 
can be implemented either as opportunistic or 
as organized strategies. In the first setting, pri-
mary care physicians and consultant specialists 
are responsible for informing individuals of the 
locally available resources for screening, and 
inviting them to take part. As there are different 
options of tests, with different profiles of advan-
tages and disadvantages regarding test intervals, 
accuracy, invasiveness and risk of harm, there 
is universal agreement recommending that the 
physician illustrates such options to individ uals 
that meet the age criteria to begin screening. 
Failure to provide such information and sug-
gestions may also have legal implications. As 
for the organized setting, several countries have 
endorsed pilot projects targeting the general 
population: the key factor for a successful and 
continuous participation in organized screen-
ing programs is unanimously considered the 
motivated involvement of primary care general 
practitioners. The Australian National Health 
and Medical Research Council (NHMRC) 
recommend organized CRC screening using 
FOBTs at least every 2 years for asymptomatic 
people over 50 years of age, and a Pilot Program 
was conducted between 2002 and 2004 in 
order to evaluate the acceptability, feasibility 
and cost–effectiveness involving approximately 
57,000 individuals in three sites in Queensland, 
Table 1. screening options for colorectal cancer in average-risk 
adults aged 50 years and older.
Tests Interval
Tests that primarily detect cancer
Guaiac FOBT with high sensitivity for cancer Annual
Immunochemical FOBT with high sensitivity for cancer Annual
Stool DNA with high sensitivity for cancer Interval uncertain
Tests that detect adenomatous polyps & cancer
Flexible sigmoidoscopy (with insertion to splenic flexure) Every 5 years
Colonoscopy Every 10 years
Double contrast barium enema Every 5 years
CT colonography Every 5 years
FOBT: Fecal occult blood test.
Adapted with permission from [28].
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Victoria and South Australia (Australia) [34].The 
Italian SCORE project has involved several 
regions using an organized approach of sigmoid-
oscopy and FOBT [35]. In the UK a similar pro-
gram is on the way [36] and other countries such 
as Japan [37], Norway [23] and France [38] have 
developed strong recommendations for screen-
ing and organized projects in the effort to reduce 
CRC mortality. Since 1996, the USPSTF has 
recommended population-wide screening of 
CRC, but no organized screening programs are 
under way. 
Compliance to screening programs remains 
the key factor for reducting mortality that will 
mostly benefit in absolute terms the screened 
population. A survey by the CDC in the USA 
has demonstrated that between 2002 and 2006 
the proportion of adults aged 50 years or older 
who had recently undergone colorectal screen-
ing had increased from 54 to 61% overall, but 
racial and ethnic minorities and those who 
reported no health insurance coverage, reported 
a consistently lower prevalence of testing [39].
Despite the various diff iculties that are 
encountered in implementing screening pro-
grams, the potential harms that may derive 
from taking part, the wide variability of test 
accuracy and operator-dependent endoscopic 
procedures, and the different choices offered, 
the age-standardized mortality rates have con-
sistently fallen somewhat in both sexes in the last 
20 years in the Western world [3]. This is a result 
of not only better treatment strategies but also 
from the continuous spreading of and adherence 
to screening tests.
The future of CRC screening envisages a rap-
idly evolving scenario, with novel technologies 
made available and an ever increasing awareness 
of the public requesting for accurate, rapid and 
minimally invasive tests. For screening pro-
grams to be effective there is a need for an active 
involvement of primary care physicians as infor-
mation providers, a choice of tests of known and 
proven accuracy, and the development of certi-
fied quality standards for the implementation of 
operator-dependent tests.
rationale of screening with CTC
Computed tomography colonography is a low-
dose abdominal CT study carried out after gen-
tly distending the large bowel with either air or 
CO
2
 introduced through a small ballooned rec-
tal tube, in a subject whose colon has been pre-
viously cleansed using some form of cathartics. 
The test is generally completed in a few minutes, 
and the CT dataset is then sent to a work station 
equipped with a dedicated software for postpro-
cessing and visualization. The work stations usu-
ally allows both automatic ‘navigation’ within 
the colon along the lumen centerline in both 
directions, and 2D visualization on different 
planes. Polyps appear as objects protruding 
within the colon lumen (Figure 1), while cancers 
may show as masses or wall thickening (Figure 2). 
In principle, CTC should make a good and 
minimally invasive screening test, as it allows 
detection of premalignant lesions and the 
visual ization of the entire colon mucosa with-
out having to introduce an endoscope within 
the colon through to the cecum, as in conven-
tional colon oscopy. However, for CTC to be 
efficiently used as a screening test, sensitivity 
and specificity need to be verified by screening 
an asympto matic population. On the one hand, 
it is essential that the detection rate of the lesions 
targeted by screening (i.e., the advanced neo-
plasia) is adequate, otherwise clinically relevant 
lesions might be missed, falsely reassuring the 
individual and delaying diagnosis. On the other 
hand, specificity must also be high, to avoid 
referring too many subjects to an unnessecary 
colonoscopy, negatively affecting costs and the 
burden to patients. Colonoscopy is an invasive 
test and carries a major adverse event rate of 3–5 
per 1000 examin ations [40]; ideally it should be 
performed as a second-level test only, follow-
ing a true-positive screening test. An overview 
on the diagnostic performance of CTC will be 
presented later in this article. Since last year, 
as a result of the accumulated evidence, CTC 
has been considered by the American guide-
lines for CRC screening as a prevention strat-
egy that can be effectively implemented in the 
general population [31].
As previously discussed, participation rate is 
just as important as performance in assessing 
the effectiveness of a screening program [41]. 
Figure 1. Colon of a 58-year-old, fecal occult blood test positive male. 
A 7‑mm pedunculated polyp of the transverse colon is visualized at CT 
colonography on the axial scan (A) and at the 3D endoluminal view (B). 
The finding is confirmed at conventional colonoscopy (C).
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Participation, or compliance, is mostly affected 
by the patient’s perception of the unpleasant-
ness and invasiveness of the test they are offered. 
Several factors influence how a screening test for 
colon cancer is perceived by the individual. Test 
acceptance is probably the single most important 
factor influencing participation. In an oppor-
tunistic setting, a poorly accepted screening test 
will cause the individual to either look for an 
alternative test, or decline screening altogether. 
In an organized setting, low participation may 
reduce its cost efficacy, again prompting regu-
latory agencies to either interrupt programs or 
seek alternative approaches [42]. Participation 
is also influenced by demographic and socio-
economic factors, test perception by the primary 
care phys ician, promotion and publicity given to 
the program, and finally the strategies chosen to 
invite individuals [43].
When considering tests for morpho logical 
examination of the colon, low acceptance may 
be due to poor tolerance, the requirement for 
bowel preparation, and/or to the test itself, 
and/or the fact that the test is a priori perceived 
as invasive and unsafe. Bowel preparation is 
often considered the most critical aspect of CTC 
[44,45], and efforts have been made to improve 
exam acceptance by avoiding strong laxatives. 
The newer fecal-tagging regimens do not require 
the preparation of a clean stool-free colon; a 
mild laxative, administered 2–3 days before 
testing, is used to soften stools so that they can 
adequately mix with the oral tagging agent, 
thus making it possible to distinguish these 
from polyps. Several different tagging protocols 
have been evaluated in terms of laxative type 
and dosage, use of iodine and/or barium agents, 
and administration timing [46–51]. Iodine-based 
tagging agents are more versatile and effective 
in marking both the feces and fluid residues 
homogeneously, at the expenses of a moderate 
laxative effect [52]. They have, however, in rare 
instances, caused severe adverse events, and for 
this reason in-hospital administration may be 
safer [53,54]. The administration of a mild laxa-
tive on the days preceding the exam, followed 
by an iodine-based solution administered 2 h 
before scanning are adequate to obtain a good 
quality CTC study [47,51]. As of today, there are 
no data on whether minimally invasive prepar-
ations, such as that reported previously, will 
favor compliance to organized screening pro-
grams; certainly this approach has made it easier 
to organize individual access to a CTC service 
and has made it possible to address safety issues. 
Fecal tagging can also improve sensitivity of 
CTC, both by highlighting polyps submerged in 
the fecal residues and by reducing false-positive 
findings (Figure 3) [48–50]. 
Individuals will comply more readily to a 
screening test if it is perceived safe and non-
invasive [41]. Bowel distension by gas is perceived 
as the most embarrassing part of CTC [55]. 
Automatic insufflators are available to regu-
late pressure during CO
2
 administration and 
improve patient acceptance [56,57]. Colon dis-
tension is the most common cause of adverse 
events at CTC, which include colon perfora-
tion, vagal reactions and respiratory distress 
[56–62]. The risk of perfor ation is approximately 
0.02–0.08%, and it has been described mostly 
in symp tomatic patients. Perforation is rare and 
usually self-contained in asymptomatic indi-
viduals [61]. No CTC-related deaths have been 
reported to date.
Some recently published articles have 
expressed concern on the extensive use of CT 
exams in pediatric- and screening-subjects [63], 
Figure 2. Colon of a 65-year-old male with blood in his stool. 
CT colonography shows a stenosing lesion of the sigmoid colon. 3D endoluminal 
CT colonography view (A), 2D axial CT colonography view (B) and surgical 
specimen (C).
Figure 3. CT colonograph of the colon of a 55-year-old female. Shows a 
peduncolated polyp in the sigmoid colon. 2D axial CT colonography prone view (A) 
and 2D axial supine view (B). The polyp appears submerged in the tagged 
iodinated residual fluid.
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and these positions may negatively affect both 
public opinion and policy makers. CTC is now 
generally performed using low-dose protocols 
(i.e., an average 4 millisievert per examina-
tion, which is less than twice the radiation dose 
that an individual absorbs yearly from natu-
ral radiations). Further evidence supporting 
this dose as safe derives from the observation 
that commercial pilots absorb approximately 
0.20 microsievert during a long intercontinental 
flight, for a total of 2–3 millisievert per year, and 
approximately 80 millisievert for a 30-year long 
career [64]. Nonetheless, no evidence of radiation-
induced cancer has yet been demonstrated in 
this professional category [65].
Computed tomography colonography also 
allows assessment of the bowel wall and abdomi-
nal cavity, thus conferring peculiar character-
istics among the available colon screening test. 
Extracolonic findings are common, and they may 
be clinically relevant in only 3–12% of the cases, 
according the different series and inclusion crite-
ria [66–69]. Relevant findings should be reported 
and alternative imaging be performed when nec-
essary, taking into consideration, however, that 
this may add to costs without a demonstrated 
benefit and be cause for undue anxiety.
Speed is also an advantage of CTC compared 
with endoscopy, as it requires altogether less than 
20 min to be performed, and individuals may 
go back to their daily activities as soon as they 
have completed the test, as no premedication is 
required. If reporting is performed by an expe-
rienced radiologist, reading time will be in the 
order of 10 min. 
In conclusion, CTC allows for the assessment 
of the entire air-to-mucosa interface of the large 
bowel, and it is well accepted since it is perceived 
as safe and well tolerated. However, there are 
some concerns regarding the exposure to low-dose 
radiation, and the unclear impact on cost:benefit 
ratio of reporting extra-colonic findings [70–72]. 
Despite the mounting evidence on the efficacy 
of using CTC as a screening test, and its inclu-
sion as such in the American guidelines for can-
cer screening strategies, most primary healthcare 
physicians still view it with distrust [73].
results of clinical trials on CTC
Computed tomography colonography has ini-
tially been demonstrated to be a valid way to 
image the colon through a series of studies in 
patients with known CRC [74–76], and studies 
on a small series of patients with colorectal pol-
yps [74,77]. Data from these preliminary stud-
ies suggest a greater than 75% sensitivity and a 
greater than 90% specificity for large colorectal 
polyps (≥10 mm in diameter) and cancers. It 
was clear that performance was highly depen-
dent on the size of the lesions: the threshold for 
a reliable detection of small lesions was approxi-
mately 5 mm. The rate of detection of larger 
polyps, and, in particular, adenomatous pol-
yps of at least 6 mm, was very satisfactory and 
in some series it approached that reported for 
conventional colonoscopy.
These promising results were confirmed by 
several single institution prospective studies on 
polyp detection rate, undertaken between 1996 
and 2003, using conventional colonoscopy as 
the reference standard [78–80]. In each study at 
least 100 patients were enrolled and the tar-
get population comprised of patients at high 
risk of CRC. For example, patients with rectal 
bleeding, positive FOBTs results, iron defi-
ciency anemia, family history of CRC or per-
sonal history of adenomas. All studies stratified 
results according to the size (≤5 mm, 6–9 mm 
and ≥10 mm) and histology type of the pol-
yps. Their results confirmed the findings of 
previous smaller studies: sensitivity was highly 
dependent on the size of the polyps, being in 
the region of 90% or more for polyps at least 
6 mm that are considered clinically relevant. 
Taking all results together, there was evidence 
that in patients at high risk of colorectal can-
cer, CTC had similar efficacy to conventional 
colonoscopy in the detection of polyps of at 
least 6 mm.
Therefore, the next step was to assess whether 
CTC could be used as a screening test, and to 
address this question it was necessary to test 
CTC performance in asymptomatic individuals. 
In 2003, Pickhardt et al. studied 1233 asymp-
tomatic average-risk subjects aged between 50 
and 79 years using double-check colonoscopy 
as the reference standard (i.e., colonoscopy 
performed by an endoscopist blinded but in 
the presence of an assistant aware of the CTC 
results) and repetition of segmental colon evalu-
ation in case of a false-negative finding [81]. All 
patients underwent same-day CTC and conven-
tional colonoscopy and the target lesions were 
adenomatous polyps measuring at least 6 mm. 
Surprisingly, the per-polyp ana lysis demon-
strated that sensitivity of CTC for advanced 
adenomas was higher than colonoscopy: 91.5% 
(54 of 59) versus 88.1% (52 of 59) respectively, 
although this difference was not significant. All 
cancers were seen at CTC. Per-patient sensitiv-
ity for polyps of at least 10 mm was 93.8%, 
even higher than colonoscopy sensitivity for 
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that category of lesions. Overall, specificity 
was almost 96%. The sensitivity decreased for 
smaller polyps but remained high, although 
less than colonoscopy, being 88.7% for polyps 
of 6 mm or more. In both the per-polyp and 
per-patient ana lysis, sensitivity of CTC was 
slightly higher than that of colonoscopy for 
adenomatous polyps of 8 mm or larger, but 
the difference was not statistically significant. 
Therefore, CTC not only had high sensitivity, 
but also maintained acceptable specificity for 
adenomas 6 mm or larger. 
Following this encouraging study, a large 
multicenter trial was designed and performed on 
asymptomatic subjects – the American College 
of Radiology Imaging Network (ACRIN) 6664 
study [82], carried out in 15 USA medical centers. 
They enrolled 2531 individuals aged 50 years or 
older with no known risk factors for CRC, and 
found a per-patient sensitivity of 90% for polyps 
larger than 10 mm. Also in this study, CTC sen-
sitivity decreased with the size of the lesions, but 
still remained between 78 and 90%, for 6 mm 
or larger and 9 mm or larger lesions, respectively. 
The accumulating evidence was fully sup-
portive of the use of CTC in screening patients 
at average risk of CRC, but there were also two 
studies [83,84], performed on symptomatic or 
higher risk patients, which concluded against 
the use of CTC. However, these studies had 
many limitations, such as the lack of experience 
of the radiologists involved in the CTC lecture, 
the inclusion of centers not very familiar with 
the CTC technique, the use of a 2D primary 
reading and the lack of fecal tagging. CTC sensi-
tivity for detecting participants with one or more 
lesions was only 39% for a threshold of at least 
6 mm [83] and 35% in the other study [84]. For a 
threshold of at least 10 mm the sensitivity was 55 
and 64% in the two studies, respectively. Even 
allowing for some of the studies limitations, such 
as a lack of reader experience and use of equip-
ment that is not state-of-the-art, those results 
raised some doubts on CTC performance away 
from referral centers.
The most recent step taken to prove the 
accuracy of CTC is represented by the study 
of Regge et  al. [85]. Their aim was to assess 
sensitivity and specificity of CTC in detect-
ing advanced neoplasia sized 6 mm or larger 
in individuals at an increased risk of develop-
ing CRC. They stratified the 934 participants 
into three groups, those with a family history of 
advanced neoplasia in first-degree relatives, those 
with a personal history of adenomas, and those 
with a positive FOBT. They found an overall 
per-patient sensitivity for nondiminutive lesions 
between 85.3 and 90.8%. These figures were 
comparable with the two large trials on asymp-
tomatic patients [81,82], but definitely higher 
than the two previously mentioned negative 
studies on increased risk subjects [83,84]. Taking 
into account the prevalence of the disease and 
the accuracy of the test in different groups of 
patients, this study concluded that CTC could 
be used instead of colonoscopy in individuals at 
increased risk of CRC due to a positive family 
or personal history of colorectal neoplasia. In 
the FOBT-positive group of patients, the results 
were not as encouraging. Considering the 50% 
prevalence of disease in this group, and a 55% 
rate of referral to colonoscopy owing to a positive 
CTC, this strategy in FOBT-positive subjects 
might not be cost effective.
In March, 2008 CTC was added as a screen-
ing test in the American Screening Guidelines 
to test average-risk subjects aged 50 years or 
older every 5 years, along with the alterna-
tives of a yearly FOBT, flexible sigmoidoscopy 
every 5 years, conventional colonoscopy every 
10 years, or double-contrast barium enema every 
5 years [31].
At present there is only one screening pro-
gram carried out using CTC: the University 
of Wisconsin (WI, USA) program that began 
in 2004 [86]. In the first year, 1192 subjects 
underwent CTC, those in whom at least one 
lesion 10 mm or larger was identified were sent 
for colonoscopy, whereas those with 6–9 mm 
polyps were offered the alternative of a follow 
up CTC. The overall CTC test-positive rate 
for 6 mm or larger polyps was 10.8%. Most 
of the patients with intermediate-size lesions 
decided to undergo follow-up CTC, thus 
overall, endoscopic referral rate for patients 
with positive findings was 6.4%. Concordant 
lesions were identified in 65 of the 71 patients 
who underwent subsequent colonoscopy, with a 
positive predictive value of 91.5%. It was con-
cluded that screening with CTC determines an 
acceptably low endoscopic referral rate and a 
high concordance of positive findings registered 
at colonoscopy.
Further evidence supporting CTC as a valid 
screening test came from the comparison of the 
parallel CTC and colonoscopy ongoing screen-
ing programs at the University of Wisconsin 
[87], in which CTC was compared with colon-
oscopy when applied to the same general screen-
ing population. The outcome measured was the 
detection rate of advanced neoplasia, which, by 
unanimous agreement, is the target lesion for 
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strategies to prevent CRC, stratified according 
to lesion size and overall polypectomy rates. This 
study indicated that polyps 10 mm or larger at 
CTC were highly predictive for advanced ade-
nomas, accounting for the great majority of all 
advanced lesions. Only 0.2% of sub centimeter 
polyps were histologically advanced, which 
emphasizes the need of a filtering strategy. The 
perforation rate of 0.2% (seven of 3163 patients) 
in the conventional colonoscopy group was 
within the expected range reported in previ-
ous series. The absence of perforation in the 
CTC screening group was largely due to both 
the minimally invasive nature of CTC and the 
decreased numbers of conventional colonos-
copy studies and polypectomies as compared 
with the primary conventional colonoscopy 
group. The strategy of not reporting diminu-
tive polyps detected during CTC screening is 
a cost-effective approach that can substantially 
reduce the rate of polypectomy and complica-
tions without negatively affecting efficacy of 
cancer prevention [70–72]. 
In 2008, Graser et  al. published a study 
comparing CTC against four already-approved 
screening tests: colonoscopy, flexible sigmoid-
oscopy, fecal immunological tests and guaiac 
FOBT [88]. CTC was confirmed as having sen-
sitivities comparable to colonoscopy for polyps 
larger than 5 mm. The debate of whether CTC 
may be used in FOBT-positive subjects is still 
open, as recent data [89] have demonstrated that 
CTC in this setting had good predictive values 
and a higher acceptability than colonoscopy. 
The results of some of the aforementioned 
screening trials are shown in Table 2.
In conclusion, CTC first gained the role as a 
clinically accurate test in symptomatic patients, 
in whom its minimal invasiveness is a great 
advantage over colonoscopy, particularly for 
frail and very ill patients, and then as a screening 
test in subjects both at an average and increased 
risk. Probably only a small proportion of high-
risk patients, such as those with hereditary non-
polyposis colon cancer, familial adenomatous 
polyposis and long-standing ulcerative colitis, 
remain unlikely candidates for CTC, consider-
ing that the narrow test repetition interval of 
1–2 years needed in such patients poses seri-
ous concerns regarding radiation exposure, 
and there is a need for frequent biopsies and 
searches for flat lesions, which are still difficult 
to identify using CTC.
Future perspective
There is solid evidence supporting CTC as an 
effective and minimally invasive test for imag-
ing the colon and one that is well accepted by 
patients. However, several issues need to be 
resolved before it may be universally perceived 
as a valid, or even the best possible, CRC screen-
ing strategy. Some are test related, others depend 
on the understanding of the natural history of 
CRC and the pathological features that affect 
growth rate and aggressiveness of this tumor [41]. 
Despite the very high prevalence of pre-
malignant colorectal lesions, their natural 
history is still not entirely understood, mostly 
because any polyp that is detected at colon-
oscopy is now removed, irrespective of its size 
and macroscopic features [31]; there are no 
accepted criteria – aside from obvious small 
hyperplastic rectal polyps – to predict whether 
a polyp does not have ‘advanced’ features, or 
whether it is instead likely to evolve into a 
malignancy, thus warranting its removal. For 
decades, polyp ectomy has been associated with 
an up to 90% reduction of the risk of develop-
ing CRC [11], thus, it would be unethical today 
not to remove a polyp during colonscopy and 
Table 2. results (per patient) of the most significant clinical trials on CT colonography.
Population Target lesion sensitivity (%) specificity (%) PPV (%) NPV (%) ref.
≥5 mm ≥10 mm Cancers ≥6 mm
Asymptomatic Adenomatous polyps 
≥6 mm in diameter
149/168
(89)
45/48
(94)
2/2
(100)
848/1065
(80)
– 604/611 
(99)
[77]
Asymptomatic Adenomas or cancer 
≥5 mm in diameter
164/210
(78)
108/120
(90)
108/120
(90)
2042/2321
(88)
169/423
(40)
2066/2108 
(98)
[78]
Asymptomatic Adenoma and advanced 
adenomas ≥5 mm 
in diameter
42/46
(91)
23/25
(92)
29/30
(97)
243/261
(93)
42/60
(70)
243/247 
(98)
[84]
Increased risk Advanced neoplasia 
≥6 mm in diameter
151/177
(85)
119/131
(91)
39/41
(95)
667/760
(88)
151/244
(62)
667/693 
(96)
[81]
Increased risk Advanced neoplasia 
≥6 mm in diameter
192/211
(91)
116/142
(82)
21/22
(95)
63/91
(69)
119/220
(87)
63/82 
(77)
[82]
NPV: Negative predictive value; PPV: Positive predictive value.
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to just follow it up, considering the unfavor-
able risk–balance of repeating a colonoscopy 
versus removing a small polyp. The evidence 
from few, relatively small observational stud-
ies carried out in the era before the introduc-
tion of colonoscopy and in the first following 
decade, shows that the growth rate of polyps 
depends on their size. Approximately 20% 
of polyps of 10 mm or larger evolve into an 
invasive cancer within 5 years [90]; a moder-
ate growth is observed instead in a minority of 
inter mediate size lesions (6–9 mm), whereas 
the rest (<6 mm) either remain stable or can 
no longer be found again [91]. There are limita-
tions to these studies: the sample size is small, 
and estimating the diameter of a small polyp 
at colon oscopy is a subjective and unreliable 
method [92,93]. Instead, CTC provides for the 
first time, an accurate and reproducible mini-
mally invasive way to measure polyp size and 
volume [94]. It is, therefore, ideal for assessing 
growth, particularly for polyps smaller than 
10 mm, for which the benefit:risk ratio may not 
be in favor of referral to polypectomy  compared 
with follow-up by CTC. 
As previously mentioned, the University of 
Wisconsin’s third-payer screening program is 
now offering a follow-up alternative to imme-
diate polypectomy for individuals with less 
than three ‘intermediate size’ (i.e., 6–9 mm) 
polyps [86]. When completed, this study will 
hopefully provide important insights into polyp 
growth patterns and form the rationale for choos-
ing the safest and more cost-effective approach 
in the average-risk individual, between CTC 
surveillance and immediate polypectomy. It is 
envisaged, however, that an aggressive approach 
will be warranted in all patients at an increased 
risk of CRC, irrespective of their polyp size, if 
a high prevalence of advanced adenomas within 
the intermediate-size category is  confirmed [85].
Another challenging issue concerns the 
further improvement of CTC accuracy and 
acceptance. First, it is essential to keep the 
radiation dose within acceptable limits for a 
screening test. New CT scanners, with more 
efficient detectors and reconstruction algo-
rithms, will probably allow us to scan patients 
using doses lower than 2 millisievert, which is 
less than the yearly background radiation expo-
sure [95,96]. Second, patient preparation, exam 
protocols and reader experience are also vital 
for this issue. In a retrospective review of data 
from a multicenter study, Doshi et al. found 
that 53% of false-negative CTC interpretations 
were due to observer errors, and another 26% 
to technical errors [97]. The authors demon-
strated that, following retrospective reconcilia-
tion, CTC sensitivity for polyps 6 mm or larger 
increased by 14%, from 76 to 90%. Technical 
errors were mainly due to excessive fluid and/or 
stool, inadequate bowel distension, and move-
ment or streak artifacts, the latter mainly from 
hip prosthesis. A standard bowel purgation 
was used in the trial, without using stool tag-
ging [84]. According to the results of a recent 
meta-ana lysis, studies performed using fecal 
tagging yielded a higher sensitivity than those 
performed without it (88% [95% CI: 84–91] 
vs 59% [95% CI: 56–63] [98]); this was likely 
due to an easier detection of polyps that remain 
‘submerged’ in both the supine and prone scans 
(Figure 3). Mistaking polyps for stool residues 
may also occur. 
As previously reported, most lesions are 
undetected by CTC owing to observer errors, 
thus, reader experience is probably the most 
important factor affecting CTC perfor-
mance [99]. Experienced radiologists fare sig-
nificantly better than trained radiologists and 
radiographers in detecting cancer and polyps 
[100,101]. Experience obviously depends on the 
number of reported CTC exams; however, it 
has not been clearly stated how many studies 
are required to provide sufficient expertise, and 
the number may also depend on the personal 
attitude of readers, as talented individuals 
might become competent after reading as few 
as 50 validated exams [100]. 
Reader performance might also be affected 
by the level of confidence in reporting a lesion. 
If a reader reports a positive finding, even 
when the confidence level is low, sensitivity 
will be privileged over specificity. The opposite 
occurs for readers who are mainly concerned 
to provide highest levels of specificity. Reading 
should probably be adjusted according to the 
characteristics of the diagnostic setting (e.g., 
when screening average-risk asymptomatic 
individuals), specificity should be privileged 
over sensitivity in order avoid an unnecessar-
ily high colonoscopy referral rate that might 
increase procedural risks and costs. Conversely, 
when dealing with high-risk individuals (e.g., 
those with symptoms or a positive FOBT), in 
whom the prevalence of clinically relevant lesions 
exceeds 40% [85], readers should aim at obtaining 
the highest  possible sensitivity. 
Performance of CTC might be improved 
by computer-aided diagnosis (CAD). Several 
small retrospective studies have demonstrated 
that detection of colorectal lesions is improved 
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by CAD [101–103]. However, a gain in sensitiv-
ity may be achieved at the expense of a lower 
specificity; CAD candidates, particularly when 
they are numerous, might force readers to revise 
their negative opinion [102]. Specificity is mostly 
reduced when the number of false-positives is 
high, and for the less experienced readers [104]. 
The type of reading paradigm and the number 
of false-positives also are factors that increase 
reading time [102,103,105], which might, however, 
be improved as readers become more confident 
in using CAD. Prospective studies should assess 
CAD performance in different realistic environ-
ments, such as the daily clinical activity or the 
implementation of CTC as a screening strategy.
The crucial factor for success and organ-
ized screening programs is a high attendance 
rate [38]. In a large study conducted between 
2002 and 2004 in northern Italy, attendance 
rates for FOBT, flexible sigmoidoscopy and 
colon oscopy were 32.3, 32.3 and 26.5%, respec-
tively [35]. An attendance rate of 28,4% was 
reported for CTC in a clinical trial conducted 
in western Australia on 2000 individuals aged 
50–69 years [106], where recruitment was per-
formed by an invitation letter, and a full bowel 
preparation was performed in all cases; partici-
pation was higher in younger individuals and in 
those with higher socioeconomic standards. A 
multivariate ana lysis has shown that individu-
als who consult their primary care physicians 
before screening, or have at least one first-degree 
relative with CRC, have a high probability 
of participation [43]. 
Computed tomography colonography may 
still have a long way to go before being per-
ceived as an effective test by healthcare opinion 
makers, and this may hinder its implementa-
tion in screening programs. In a recent survey 
completed by 1266 US physicians, only 22.6% 
perceived CTC as very effective, and as few 
as 4.8% would routinely recommended it for 
CRC screening [42]. Randomized trials compar-
ing detection and attendance rate of CTC to 
other screening modalities might bring some 
insight on the possible future role of CTC in 
CRC screening. Two such trials are now start-
ing recruitment. In The Netherlands a trial 
will compare the participation rate and yield of 
CTC and colonoscopy in a randomized study 
involving 7500 asymptomatic individuals aged 
50–74 years [201]. In Italy, the randomized trial 
Protèus will compare participation and detec-
tion rate of CTC and flexible sigmoidoscopy in 
25,000 asymptomatic individuals aged 58 years 
or older; all CTC studies will be sent to a single 
center where they will be interpretted by expe-
rienced readers with the aid of a CAD system. 
Both trials will also perform a cost–effectiveness 
ana lysis, as evidence of sustainable costs is 
essential for public health systems to finance a 
given  screening program. 
In conclusion, CTC scores highly as an effec-
tive screening modality. It explores the entire 
colon, there is no need for a strong bowel pur-
gation, it is well tolerated without the need for 
sedation, severe complications are extremely 
rare in asymptomatic subjects and its perfor-
mance is similar to traditional colonoscopy 
for clinically relevant lesions, being equally 
effective in asymptomatic individuals both at 
an average and increased risk of CRC. Owing 
to this evidence, CTC has now been included 
in the American Cancer Society Guidelines as 
a test for opportunistic screening in average-
risk individuals, beginning from the age of 
50 years [28]. Collaterally, CTC also provides 
a formidable tool to clarify the natural history 
of CRC, which is largely unknown. This may 
heavily affect future strategies for screening 
and follow-up, providing us with the evidence 
for deciding whether small- and intermediate-
colorectal polyps may be left in place or should 
be systematically removed. There are, however, 
gray areas: CTC performance is not likely to 
be uniform, recent studies have reported low-
sensitivity and specificity values, the technique 
is not yet standardized, reading times are still 
relatively long and the role of CAD systems is 
not yet clarified. Efforts will have to be made 
towards standardization, and efficient train-
ing strategies that need be implemented and 
adjusted to the target population. Healthcare 
policy makers and primary care physicians are 
still quite skeptical with regards to the role of 
CTC in mass-screening programs. In future, 
large randomized trials should provide answers 
to important issues, such as attendance rate and 
cost–effectiveness of screening CTC, hopefully 
opening the way for its more widespread and 
confident use.
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executive summary
Colorectal cancer has heavy social & financial costs
  Colorectal cancer is the third most common malignancy in the Western world with the second highest mortality rate and its frequency is 
also increasing in poor countries.
  The incidence of colorectal cancer is approximately 50 in 100,000 people/year, with a prevalence of 60 individuals in 1000 inhabitants, 
with an estimated 210,000 deaths yearly in Europe.
  Costs of chemotherapy have increased by over 300‑times in the last 5 years, up to €23,000 for a single course. Caring for one patient 
with late‑stage colorectal cancer costs approximately €80,000.
Colorectal cancer is a preventable disease
  The majority of cases arise in pre‑existing adenomatous polyps that undergo a slow malignant transformation spanning more than 
10 years.
  Advanced adenomas are the most likely premalignant lesions that progress to cancer, and they are defined by size (at least 10 mm in 
diameter) or histological features (villous component or high‑grade dysplasia).
  Identification and removal of advanced adenomas reduces the risk of developing colorectal cancer by more than 90%.
  Early colorectal cancers localized in the submucosa are mostly asymptomatic and their treatment results in a 5‑year survival rate of 
approximately 90%.
  Advanced adenomas and early cancer form the advanced neoplasia that is the best target for screening strategies.
Prevention strategies are mainly hindered by compliance
  No more than 60% of individuals who should benefit from a screening test have actually undertaken one.
  Colonoscopy performed at the age of 55 years is theoretically the most efficient way to identify and treat advanced neoplasia, but it is 
scarcely accepted by healthy individuals.
  Even compliance to annual or biannual fecal occult blood tests is also suboptimal.
CT colonography is the best candidate for an effective & well accepted screening test
  CT colonography (CTC) allows detection of premalignant lesions and the visualization of the entire colon mucosa.
  CTC is minimally invasive, and prior bowel cleansing can be obtained without using strong laxatives.
  CTC has a sensitivity over 90% for advanced neoplasia and a specificity exceeding 95%.
  CTC has been included as a valid alternative screening test in several guidelines.
Future perspective
  With the help of computer‑aided diagnostic systems, CTC may become an easily standardized and widely used test for screening 
average‑risk individuals older than 50–55 years of age.
  There is a valid rationale for avoiding polypectomy in cases where polyps smaller than 10 mm are found at screening CTC, and offering 
the patient the possibility of CTC follow‑up. This may help clarify the natural history of small polyps that are not likely to progress to 
cancer, thus reducing the costs and risks associated with indiscriminate polypectomies.
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